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ORIGINAL ARTICLE

Prevalence of Childhood Epilepsy in
Canada
AN. Prasad, X. Sang, BA. Corbett, J.G. Burneo
ABSTRACT: Rationale: Few data exist on the frequency and burden of childhood epilepsy in Canada and on the impact in the general
population. We have assessed the point prevalence of childhood epilepsy in Canada. Methods: We analyzed data from the National
Longitudinal Survey of Children and Youth (N=20 025 for Cycle 2, and N= 31 960 for cycle 3). Each cycle was collected over a two
year period (2: 1996-1997, 3: 1998-1999). In the survey the following specific question was asked to the person most knowledgeable in
the household: "Does the child have any of the following long-term conditions that have been diagnosed by a health professional?" The
list of responses included Epilepsy and certain co-morbid conditions. In addition, a subsequent question identified whether the condition
was treated by means of a specific anticonvulsant medication, (anticonvulsants or anti-epileptic pills?). Prevalence was based on the
national standard population at the time of each survey. Results: In Cycle 2,80 of 20 025 subjects from 0 to 13 years old were described
to have the diagnosis of epilepsy, yielding a weighted point prevalence of 4.03 per 1 000. In Cycle 3 161 of 31 960 children from 0 to
15 were described as having epilepsy, yielding a weighted point prevalence of 5.26 per 1 000. The rate of epilepsy was higher for males
and increases with age. Conclusion: The overall rates for this age cohort are consistent with those obtained in other developed countries
and seem to coincide with rates for youth and adults in Canada.

RESUME: Prevalence de I'epilepsie chez l'enfant au Canada. Justification : II existe peu de donnees sur la frequence et le fardeau de I'epilepsie
chez l'enfant au Canada et sur son impact dans la population en general. Nous avons evalue la prevalence ponctuelle de I'epilepsie chez l'enfant au
Canada. Methode : Nous avons analyse les donnees de PEnquete longitudinale nationale sur les enfants et les jeunes (cycle 2 : N = 20 025 ; cycle 3 :
N = 31 960). Les donnees de chaque cycle ont ete recueillies en deux ans (cycle 2 : 1996-1997 ; cycle 3 : 1998-1999). Au cours de l'enquete, les
questions specifiques suivantes ont ete posees a la personne la mieux renseignee du menage : "L'enfant souffre-t-il de l'une ou l'autre des maladies
chroniques suivantes, diagnostiquee par un professionnel de la sante?" L'epilepsie ainsi que certaines comorbidites faisaient partie de la liste des
reponses possibles. De plus, une question subsequente demandait si la maladie etait traitee au moyen d'un anticonvulsivant specifique (pilules anticonvulsivantes ou antiepileptiques?). La prevalence etait basee sur la population nationale au moment de chaque enquete. Resultats: Au cours du cycle
2, 80 des 20 025 sujets de 0 a 13 ans ont ete identifies comme ayant recu un diagnostic d'epilepsie, ce qui correspond a une prevalence ponctuelle
ponderee de 4,03 par 1 000. Au cours du cycle 3, 161 des 31 960 enfants de 0 a 15 ans ont ete rapportes comme etant atteints d'epilepsie, ce qui
correspond a une prevalence ponctuelle ponderee de 5,26 par 1 000. Le taux d'epilepsie etait plus eleve chez les garcons que chez les filles et il
augmentait avec l'age. Conclusion : Les taux globaux pour cette cohorte d'age sont en accord avec ceux obtenus dans d'autres pays industrialises et
semblent coi'ncider avec les taux rapportes chez les jeunes et les adultes au Canada.
Can. J. Neurol. Sci. 2011; 38: 719-722

There are few population-based studies on the prevalence of
seizures disorders in children1"3 as prevalence studies are usually
based on the case ascertainment of epilepsy from hospital visits,
clinic databases, electroencephalogram (EEG) records, and
emergency room records4. Furthermore, few Canadian data exist
on the frequency of epilepsy, particularly in the childhood
population56. Data on prevalence rates of childhood epilepsy
have varied from three to six cases per 1 000 between studies of
different age groups7,8.
Evaluating data from the Ontario Health Survey (OHS), and
later from the National Population Health Survey (NPHS) and
the Canadian Community Health Survey (CCHS), a point
prevalence of self-reported epilepsy of 5.2 to 5.8 per 1 000
population was obtained 26 . The OHS is an extensive survey in
the Province of Ontario, while the NPHS and the CHS are
national surveys, providing health-related and sociodemographic information in the Canadian population, but
include mostly patients older than 12 years of age.

Using data from Cycles 2 and 3 of the National Longitudinal
Survey of Children and Youth (NLSCY), we assessed the
prevalence of childhood epilepsy in Canada.
METHODS

The National
(NLSCY)

Longitudinal

Survey of Children and Youth

The NLSCY is a population based, long-term survey
designed to measure characteristics and life experiences of
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children and youth in Canada as they grow from infancy to
adulthood. The objectives of NLSCY are to determine the
prevalence of various biological, social and economic
characteristics and risk factors of children and youth in Canada;
to monitor the impact of such risk factors, life events and
protective factors on the development of these children; and to
provide this information to policy and program officials for use
in developing effective policies and strategies to help young
people live healthy, active and rewarding lives.
The NLSCY was conducted bi-annually from 1994 to 2003.
The target population for Cycle 1 consisted of 22 831 Canadian
children aged newborn to 11 years-of-age selected from three
sources: (1) Statistics Canada's Labor Force Survey (LFS); (2)
Statistics Canada's National Population Health Survey (NPHS).
(3) Yukon and Northwest Territories. These children selected in
Cycle 1 were followed from 1994 to 2003 as the longitudinal
sample. In subsequent Cycles 1 through 4, additional samples
were added to fill the birth to two year old age cohort; therefore,
these cycles can be analyzed as cross-sectional or used for
longitudinal analyses.
Data were collected by face-to-face or telephone interview
using computer-assisted interviewing (CAI). Questions were
asked to the respondent in the home or by telephone and directly
entered into a computer by the interviewer. The person that is
most knowledgeable (PMK) about the child was asked to
complete the questions.
Case ascertainment and analysis
Two cycles of the NLSCY data were analyzed. Cycle 2 was
conducted from 1996 to 1997 with a sample size of 17 832 and
cycle 3 was conducted from 1998 to 1999 with a sample size of
27 668. The presence of epilepsy was probed by a specific
question in the survey. Question HLT-Q45 in the survey asked
the PMK "Does the child have any of the following long-term
conditions that have lasted or are expected to last six months or
more and have been diagnosed by a health professional".
Epilepsy is one of the responses in the list along with allergies,
bronchitis, heart condition or diseases, cerebral palsy, kidney
condition or diseases and mental handicap. In addition, a
subsequent question (HLT-Q51D) identified whether the

condition was treated by means of a specific anticonvulsant or
antiepileptic medication.
Cross-sectional samples were used from Cycles 2 and 3.
Cycle 2 was collected in 1996-1997 and Cycle 3 was collected
in 1998-1999. New respondents from 0 to 2 were added to the
longitudinal sample in each cycle (2 and 3). Cross-sectional
weights were calculated for each cycle to produce population
estimates that were representative of the Canadian Census
Population for each data collection period.
The numerator was the weighted cases, and the denominator
was the weighted persons at risk. Data was analyzed using SPSS
version 13.0. In addition, 95% confidence intervals were
calculated using the exact method.
Sampling weights were used with all calculations to account
for the complex sampling design of the study. The sample
weights represent the inverse probability of being sampled. For
further information on weighting or other methodological issues
relating to the NLSCY see the user guide, available at:
http://www.statcan.gc.ca/dli-ild/data-donnees/ftp/nlscyelnej/nlcsy-elnej-cycle3-eng.htm.
RESULTS

Prevalence of Epilepsy (Table 1)
In the NLSCY, the prevalence of epilepsy in Canadian
children between 0-13 years (Cycle 2) was 4.03 per 1 000
(95%CI; 4.02,4.04) and in the age groups 0-15 years (Cycle 3),
increased to 5.26 per 1 000 children (95% CI; 5.25, 5.27). A
slight male preponderance was noted (M: F, 4.84:3.18 per 1 000
children) in Cycle 2. This effect was more pronounced in Cycle
3 (M:F, 6.45:4.00 per 1 000 children).
Treatment of Epilepsy
In a second analysis we used an item that asked whether the
child was treated for six months or longer with anticonvulsants
or antiepileptic drugs (HLTQ51D). A new variable for treated
epilepsy was computed if the child had been diagnosed with
epilepsy by a health professional (HLTQ45) and was treated for
six months or longer with anticonvulsants or antiepileptic drugs.
The prevalence of treated epilepsy dropped to 2.75 per 1 000

Table 1: Prevalence of self reported Epilepsy in Canadian children using NLSCY data

Child has epilepsy
Preschool (0-5)
School aged (6+)
Males with epilepsy
Females with epilepsy
Child taking AED
Child has epilepsy & on AED

Prevalence per 1,000 (95% CI)
Cycle 2
Cycle 3
0-13 years old
0-15 years old
5.26 (5.25, 5.27)
4.03 (4.02, 4.04 )
0.90
1.43
6.31
7.47
4.84 (4.82, 4.86)
6.45 (6.43, 6.47)
3.18 (3.16, 3.20)
4.00 (3.98, 4.02)
4.84 (4.82, 4.86)
5.95 (5.93, 5.97)
2.75 (2.74, 2.76)
3.99 (3.98, 4.00)
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(95%CI; 2.74,2.76) in Cycle 2 and 3.99 per 1 000 (95%CI; 3.98,
4.00) in Cycle 3. The prevalence figures for children who were
treated with anticonvulsants were slightly higher than the
prevalence figures for respondents who answered in the
affirmative to the question HLTQ45 (4.84 vs 4.03 amongst Cycle
2 respondents and 5.95 vs. 5.26 amongst cycle 3 respondents)
(Table 1).
Finally, in the cohort of newborn to 15 year olds nearly
16 000 children and youth were diagnosed with epilepsy in
Canada during the 1998-1999 data collection period. These
estimates are based on a weighted population based sample from
Cycle3oftheNLSCY.
DISCUSSION

The principal aim of this study was to calculate prevalence
rates for epilepsy using data from the NLSCY survey. The
NLSCY survey is longitudinal and truly population based. On
account of its longitudinal nature one could examine age and
time dependent changes in prevalence rates. The calculated
prevalence rates from our analysis are remarkably similar to
prevalence data estimated in other comparable childhood
populations in the developed world. From this analysis, first, one
is struck by the similarity and stability of prevalence rates from
other Canadian studies with different population and age cohorts.
Second, despite the different methods of case ascertainment (i.e.,
hospital based, administrative vs. population survey) employed
in other studies, prevalence estimates across age groups are
remarkably stable.
The prevalence rate in children increases in the school age
cohort. This is not unexpected as more new cases are added in,
while children diagnosed in previous years may not have
achieved a remission. Thus the changes in prevalence between
cycles can be explained in part by an increase in the age range
studied, the population sample and biological plausibility.

Furthermore, a male preponderance in prevalence rates is
noted in both cycles. Treatment prevalence by AED use is
similar to the estimates of another study on Canadian children in
Manitoba using data from the Population Health Research Data
Repository (Table 2) 9 .
The prevalence of treated epilepsy (i.e. patient diagnosed and
on AED) and the prevalence rates of diagnosed epilepsy are not
concordant. The difference in rates (diagnosed epilepsy-treated
epilepsy) though small (1.28 per 1 000 in Cycle 2 and 1.27 per
1 000 in Cycle 3) could be accounted for by several factors.
Some of the common benign childhood epilepsies may not be
treated with regular AED's (benign rolandic epilepsy) or
treatment may be deferred until several epileptic seizures occur.
In such situations it is not uncommon for children not to be on
antiepileptic medication, while they carry a diagnosis of
epilepsy. Many parents may carry the misperception that their
children may have seizures, but may not be specifically told that
their child has epilepsy. Another discordant note is struck by the
observation that the proportion of children taking AED's is
higher than those diagnosed with epilepsy. The off label use of
AEDs in childhood neurological and psychiatric conditions has
increased over the last two decades10. AEDs are presently used
for treatment of chronic pain, headaches, Attention Deficit
Hyperactivity Disorder, and psychoses. This expansion of off
label use of antiepileptic drugs could likely account for the
observed differences.
The study is important because it provides national data, as
the previous available studies in children came from selected
regions of Canada5,9, and because this type of study provides an
idea of the burden of epilepsy on the childhood population and
may help determine the need for health care, and contribute to
future, more complex research6.
There are several limitations imposed by the nature of the
condition being studied and the survey methodology used. The

Table 2: Prevalence of Epilepsy in children in other national and international studies
Reference

Age Range

Data Source/Region & Country

Larsson & Eeg-Olofsson
(2006)
Eriksson & Koivikko
(1997)
Hauser & Kurland
(1991)
Wiebe et.al
(1999)
Tellez Zenteno et al
(2004)
Tellez Zenteno et al
(2004)
Kozyrskyj & Prasad
(2004)

1 m-16 years

Hospital Register
Uppsala, Sweden
Hospital Register
Finland
Rochester Epidemiology Project,
Minnesota
Ontario Health Survey,
Ontario, Canada
National Population Health Survey,
Canada
Community Health Survey
Canada
Population Health Research Data
Repository
Manitoba

0-15 years
0-11 years
12-14 years
0-11 years
12-14 years
0-11 years
12-14 years
0-11 years
12-14 years
0-4 years
5-9 years
10-14 years
15-19 years

Volume 38, No. 5 - September 2011
https://doi.org/10.1017/S0317167100054081 Published online by Cambridge University Press

Prevalence per 1,000
(Confidence intervals)
3.4
3.9
2.6
6.2
3.1
5.7
2.5 (2.1-3.0)
4.4 (3.4-5.8)
Not evaluated
2.9(1.9-4.0)
3.46(2.96-4.05)
3.63(3.13-4.17)
4.61(4.04-5.26)
7.19(6.46-8.00)
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condition of epilepsy is dynamic; as children grow older new
cases can be diagnosed in some children and others may go into
remission. There are no data on specific types of seizures or
epilepsy syndromes collected in the survey. Definitions of active
epilepsy and epilepsy in remission are not specified; therefore it
is difficult to capture the total number of children who are
impacted by epilepsy during childhood. Furthermore, the
surveys did not include populations in rural, remote areas, and
Indian Reserves. The exclusion of the latter population group is
of importance as the epidemiology of epilepsy could be different
due to different genetic and socio-demographic factors.
However, the survey provides accurate information about
Canadian children with epilepsy.
It may be argued that self-report measures used in survey
methodology may be less reliable than measures diagnosed by a
physician. Disorders that are rare or uncommon may give small
sample sizes and result in a high sampling variance. To minimize
such errors bootstrap weights have be used to calculate sampling
variance. Results are reported with their confidence intervals and
these are sufficiently narrow and comparable to results of other
studies (Table 2) supporting the validity of our results. There are
other sources of nonsampling errors that could potentially
influence results namely; response errors due to sensitive
questions, poor memory and recall, translated questionnaires,
approximate answers, conditioning bias, non response errors and
coverage errors. Statistics Canada makes several adjustments to
minimize bias and reduce the effects of such nonsampling errors.
Despite these limitations, we have demonstrated that the survey
data is sufficiently robust to support analysis of a sub population
of children with epilepsy. We hope to extend our analysis to
examine comorbid conditions associated with childhood
epilepsy, behavioral effects and cognitive outcomes in future
studies. We will also provide Statistics Canada with feedback as
to how some of the limitations of the current survey could be
overcome to improve the quality of the data collected on child
health issues pertaining to epilepsy.
Thus, we conclude that the NLSCY survey provides useful
and valid estimates of prevalence of epilepsy and use of AED's
in Canadian children from birth to 15 years. Future studies are
planned to model socio-demographic and maternal factors in
causation, as well as to analyse information on co-morbidities
and cognitive and developmental outcome of children with
epilepsy.
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